ArticleMolecular psychiatry2026
Copy number variant scores are associated with cerebrovascular pathology in aging.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Late-onset Alzheimer's disease (LOAD) is the most common cause of dementia in older adults, with specific genomic copy number variants (CNVs) implicated in its pathology. However, the aggregate burden of genome-wide CNVs in dementia and age-related neuropathologies is uncharacterized. This study investigated the association between genome-wide CNV scores (CNV-S) and dementia, as well as LOAD-related neuropathologies, in 1011 elderly participants (mean age 88.06) from two ongoing US-based longitudinal clinical-pathological cohort studies who were initially dementia-free and consented to brain donation upon death. Participants exhibited varying cognitive statuses at death (429 dementia, 258 mild cognitive impairment, 324 cognitively normal). We evaluated effects of (1) eight individual-level CNV-S based on gene loss intolerance and dosage sensitivity; (2) a single nucleotide polymorphism (SNP)-based LOAD polygenic score (PGS-LOAD) calculated using Bayesian continuous shrinkage; and (3) covariates (age, sex, and education). Outcomes included cognitive scores across 19 tests, clinical diagnoses of Alzheimer's disease or mild cognitive impairment, and four LOAD-related neuropathologies assessed postmortem. Analyses identified 4867 CNVs (3918 deletions, 949 duplications) mapped to 3211 genes. Higher deletion CNV-S were significantly associated with increased cerebrovascular pathologies (pLI: β = 0.14, 95% CI [0.08, 0.21]; LOEUF: β = 0.14, 95% CI [0.08, 0.20]; pHI: β = 0.15, 95% CI [0.08, 0.21]; binarized pHI: β = 0.14, 95% CI [0.08, 0.21]). Models predicting cerebral atherosclerosis that included deletion CNV-S significantly outperformed models based on only PGS-LOAD (R
Identifiers
42399414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.